Terms: = Breast cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
866 results:
1. Epithelial Expressed b7-h4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative breast cancer.
Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
[TBL] [Abstract] [Full Text] [Related]
3. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/pd-l1 signaling.
Wang S; Li J; Hong S; Wang N; Xu S; Yang B; Zheng Y; Zhang J; Pan B; Hu Y; Wang Z
J Exp Clin Cancer Res; 2024 Apr; 43(1):121. PubMed ID: 38654356
[TBL] [Abstract] [Full Text] [Related]
4. Clinical relevance of glycosylation in triple negative breast cancer: a review.
Chakraborty M; Kaur J; Gunjan ; Kathpalia M; Kaur N
Glycoconj J; 2024 Apr; 41(2):79-91. PubMed ID: 38634956
[TBL] [Abstract] [Full Text] [Related]
5. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular pd-l1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract] [Full Text] [Related]
6. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and pd-l1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
7. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
8. Suppression of AGRN enhances CD8+ T cell recruitment and inhibits breast cancer progression.
Tao J; Shen L; Zhuang M; Zhai C; Zeng H; Mao Y; Liu X
FASEB J; 2024 Apr; 38(7):e23582. PubMed ID: 38568853
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S; Kraxner A; Cheng WY; Ou Yang TH; Flores M; Theiss N; Tsao TS; Andersson E; Harring SV; Bröske AE; Ceppi M; Teichgräber V; Charo J
Front Immunol; 2024; 15():1352615. PubMed ID: 38558814
[TBL] [Abstract] [Full Text] [Related]
10. Formononetin Restrains Tumorigenesis of breast Tumor by Restraining STING-NF-κB and Interfering with the Activation of pd-l1.
Liu H; Wang Z; Liu Z
Discov Med; 2024 Mar; 36(182):613-620. PubMed ID: 38531802
[TBL] [Abstract] [Full Text] [Related]
11. Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy.
Hu N; Xue H; Zhang T; Fan Y; Guo F; Li Z; Huo M; Guan X; Chen G
Biomed Pharmacother; 2024 May; 174():116482. PubMed ID: 38520866
[TBL] [Abstract] [Full Text] [Related]
12. Assessing the relationship between tumor-infiltrating lymphocytes and pd-l1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
[TBL] [Abstract] [Full Text] [Related]
13. Programmed Nanocloak of Commensal Bacteria-Derived Nanovesicles Amplify Strong Immunoreactivity against Tumor Growth and Metastatic Progression.
Zhang J; Wan S; Zhou H; Du J; Li Y; Zhu H; Weng L; Ding X; Wang L
ACS Nano; 2024 Apr; 18(13):9613-9626. PubMed ID: 38502546
[TBL] [Abstract] [Full Text] [Related]
14. Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models.
Umer BA; Noyce RS; Kieser Q; Favis NA; Shenouda MM; Rans KJ; Middleton J; Hitt MM; Evans DH
PLoS One; 2024; 19(3):e0298437. PubMed ID: 38498459
[TBL] [Abstract] [Full Text] [Related]
15. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
Wu J; Wang W; Gao L; Shao X; Wang X
Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
[TBL] [Abstract] [Full Text] [Related]
16. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-pd-l1 immune-mediated tumor cell killing.
Demeule M; Currie JC; Charfi C; Zgheib A; Cousineau I; Lullier V; Béliveau R; Marsolais C; Annabi B
Front Immunol; 2024; 15():1355945. PubMed ID: 38482021
[TBL] [Abstract] [Full Text] [Related]
17. The enhanced antitumor activity of bispecific antibody targeting PD-1/pd-l1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract] [Full Text] [Related]
18. Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.
Zhu L; Man CW; Harrison RES; Wu Z; Limsakul P; Peng Q; Hashimoto M; Mamaril AP; Xu H; Liu L; Wang Y
ACS Nano; 2024 Mar; 18(11):8531-8545. PubMed ID: 38456901
[TBL] [Abstract] [Full Text] [Related]
19. Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota.
Li H; Dong T; Tao M; Zhao H; Lan T; Yan S; Gong X; Hou Q; Ma X; Song Y
Food Funct; 2024 Apr; 15(7):3463-3478. PubMed ID: 38456333
[TBL] [Abstract] [Full Text] [Related]
20. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract] [Full Text] [Related]
[Next]